A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer


Tas F. , Guney N. , Derin D., Aydiner A. , Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, ss.156-160, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 13 Konu: 2
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1007/s10147-007-0740-4
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.156-160

Özet

Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.